Fox Christine 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 6, 2026

AI-generated summary of this filing

Updated Mar 6, 2026

TEVA EVP Christine Fox Sells 9,098 Shares

What Happened

Christine Fox, EVP, U.S. Commercial of Teva Pharmaceutical Industries (TEVA), had restricted share units vest and completed related derivative transactions on March 4, 2026. She sold 9,098 shares in an open‑market transaction at a weighted average price of $32.46 for proceeds of $295,362. The filing also reports conversion/exercise entries for 20,461 derivative shares and a new grant of 50,643 restricted share units (RSUs) on the same date.

Key Details

Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (appears timely).
Open‑market sale: 9,098 shares, weighted average price $32.46, total reported proceeds $295,362. Price range for the sale: $32.095–$33.30 (multiple transactions, per filing).
Derivative activity: two exercise/conversion (code M) entries for 20,461 shares and one derivative disposal reported at $0 (per filing).
Grant: 50,643 RSUs awarded on March 4, 2026 (see vesting schedule in footnote).
Footnotes: sale executed under a Rule 10b5‑1 plan adopted Aug 11, 2025 (F3); the sale of shares was to cover tax withholding on vesting RSUs (F4); RSU vesting schedules provided (F6, F7).
Shares owned after the transactions: not specified in the excerpted details of the filing.

Context

This activity looks like routine compensation settlement: RSUs vested, some shares were converted/settled, and a portion was sold (through a 10b5‑1 plan) to cover tax obligations. Such tax‑withholding sales are common and do not by themselves indicate a change in insider sentiment. Purchases are generally a stronger signal of insider bullishness; this filing primarily reports a sale and a new RSU grant (award).

Form 4

Period: 2026-03-04

EVP, U.S. Commercial

Transactions

Exercise/Conversion
Ordinary Shares
[F1][F2]
2026-03-04+20,461→ 84,108 total
Sale
Ordinary Shares
[F1][F3][F4][F5]
2026-03-04$32.46/sh−9,098$295,362→ 75,010 total
Exercise/Conversion
Restricted Share Units
[F2][F6][F1]
2026-03-04−20,461→ 40,923 total
→ Ordinary Shares (20,461 underlying)
Award
Restricted Share Units
[F2][F7][F1]
2026-03-04+50,643→ 50,643 total
→ Ordinary Shares (50,643 underlying)

Footnotes (7)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
[F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
[F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F6]Restricted share units were granted on March 4, 2024, with 20,461 vested on each of March 4, 2025 and March 4, 2026, 20,461 vesting on March 4, 2027, and 20,462 vesting on March 4, 2028.
[F7]Restricted share units were granted on March 4, 2026, with 12,660 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 12,663 vesting on March 4, 2030.

Signature

/s/ Dov Bergwerk as attorney-in-fact for Christine Fox|2026-03-06

1 file